Ocuphire Pharma
what important efficacy signal safety label expansion guidance physician patients efficacy signal safety patient experience in drops | Ocuphire Pharma
Company
Deck Type
Deck date
January 2022
Slide
59 of 114
Related slides by other companies
Aeglea BioTherapeutics
Investor Presentation
April 2023
program summary | Aeglea BioTherapeutics
Alkermes
Investor Day
March 2021
advancing across key domains submission of data for presentation at upcoming congresses artistry updated safety and efficacy data artistry dose and initial efficacy and safety data advance ongoing studies advance interactions with regulatory authorities initiate studies in mucosal melanoma and platinum resistant ovarian cancer to support potential registration pursue strategic collaborations to expand development program | Alkermes
Aeglea BioTherapeutics
Investor Presentation
May 2023
program summary | Aeglea BioTherapeutics
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights